Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Early Phase I Study of the Pharmacodynamics of WEE1 Inhibitor, ZN-c3, in Metastatic Solid Tumors

NCT05368506 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT05368506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05368506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Early Phase I Study of the Pharmacodynamics of WEE1 Inhibitor, ZN-c3, in Metastatic Solid Tumors
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 1
Overall status
Withdrawn
Start date
July 30, 2023
Completion date
July 31, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced fallopian tube carcinoma, advanced ovarian carcinoma, advanced primary peritoneal carcinoma, anatomic stage iv breast cancer ajcc v8, metastatic triple-negative breast carcinoma, stage iii fallopian tube cancer ajcc v8, stage iii ovarian cancer ajcc v8, stage iii primary peritoneal cancer ajcc v8, stage iv fallopian tube cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv primary peritoneal cancer ajcc v8